Vemurafenib

Drug Profile

Vemurafenib

Alternative Names: PLX-4032; R-7204; RG-7204; RO-5185426; Zelboraf

Latest Information Update: 02 Jun 2017

Price : $50

At a glance

  • Originator Plexxikon
  • Developer Chugai Pharmaceutical; Genentech; Georgetown University; H. Lee Moffitt Cancer Center and Research Institute; Melanoma Research Alliance; Memorial Sloan-Kettering Cancer Center; Plexxikon; Roche; University College London; University Hospital Tubingen
  • Class 2 ring heterocyclic compounds; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase II Brain metastases; Colorectal cancer; Haematological malignancies; Multiple myeloma; Non-small cell lung cancer; Solid tumours; Thyroid cancer

Most Recent Events

  • 12 May 2017 Phase-II clinical trials in Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater) in United Kingdom (PO) (NCT02314481)
  • 02 Mar 2017 Georgetown University, Genentech and Melanoma Research Alliance terminate a phase II trial for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA due to recruitment difficulties (PO) before March 2017 (NCT01813214)
  • 11 Jan 2017 Genentech collaborates with NCI Formulary to co-develop vemurafenib in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top